Eli Lilly and Hong Kong-listed Laekna will collaborate to develop an experimental obesity drug that aims to help patients ...

Silence Therapeutics presented what seemed like positive data on zerlasiran, its experimental drug for reducing ...

At The Unruly Pig in Suffolk, they’ve cracked the gastropub code: unapologetically bold flavours, devilishly clever dishes ...

Investors are fearful RFK Jr.'s critical stance on weight loss drugs could impact pricing or Medicare coverage, but BMO says ...

As you know, our shared priority in TIME101 is to be a cash flow positive company in 2025. Reaching this goal will allow us ...

A short strangle on Eli Lilly will generate $1,125 in option premium and takes advantage of the current high level of implied volatility.

Verge Genomics announced that Eli Lilly (LLY) has opted to pursue the development of therapeutics against two validated drug targets for ...

Readouts from Novo Nordisk and Viking Therapeutics at AASLD 2024 strengthen the argument for GLP-1 therapies as an emerging ...

The pharmaceutical companies behind Ozempic, Wegovy and other weight-loss meds push to prevent compounding pharmacies from ...

GLP-1 drugs like Ozempic are injectable medications—but a strange new market has emerged selling oral “compounded” versions ...

NEW YORK (Reuters) - About 44% of U.S. employers with 500 or more employees cover drugs for weight loss in 2024, up from 41% ...

Obviously, this list will be heavy on the Cucalorus Film Festival this week, but it also includes several non-Cucalorus ...